Rochester, NY 8/28/2009 10:07:46 PM
News / Business

Cardium Therapeutics Inc. CXM, stock market updates $1.92 at open market

Cardium Therapeutics Inc. CXM

Cardium Therapeutics, release its market trade $1.92at open market posted on average volume hit $162,265 shares. The stock has traded within a 52-week range of $1.92 low and $1.99 high.

Cardium Therapeutics, Inc. focuses on the acquisition and development of innovative bio-medical product opportunities and businesses that have the potential to address unmet medical needs and definable pathways to commercialization, partnering, and other economic monetizations.

http://StockEinstein.com offers free daily stock alerts on companies ready to run.  Scroll to BOTTOM of this page for free stock alerts, or visit our site.

Last Trade:    1.86   
Day's Range:      1.86 - 1.99
52wk Range:    0.38 - 3.10
Change:             Down 0.06 (3.12%)
Volume:            31,262
Avg Vol (3m):  162,265


ABOUT Cardium Therapeutics Inc.

Cardium Therapeutics, Inc. focuses on the acquisition and development of innovative bio-medical product opportunities and businesses that have the potential to address unmet medical needs and definable pathways to commercialization, partnering, and other economic monetizations. The company’s investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of innovative therapeutic products for tissue repair and cardiovascular indications. Its products include Generx, a DNA-based growth factor therapeutic that is in Phase III clinical stage designed to leverage the body’s natural healing processes in response to repeated ischemic stress; Corgentin, a pre-clinical stage product, which enhances myocardial healing in and around the infarct zone when used as an adjunct to existing vascular-directed pharmacologic and interventional therapies; and Excellarate, a tissue repair’s product candidate that is in Phase IIb clinical trial for the treatment of non-healing diabetic foot ulcers. The company was founded in 2003 and is headquartered in San Diego, California.

About Stock Einstein

StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance.  We utilize not only software, but time tested criteria to uncover these potential winners.  When these benchmarks are reached or exceeded, our subscribers are immediately notified.

This service is free and available only to subscribers. 
Scroll to the bottom of this page to signup for free stock alerts and visit our site.

Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php

IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment.  Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses.  Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.